Trial abstract · §3
BPC-PH2-UC — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Clinical remission in ulcerative colitis | The Institute has identified references to a clinical programme under this compound but has not obtained a published report, and grades all human claims very low certainty on that basis | Not rated |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for BPC-157 from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Injection-site reaction | — | — | Reported anecdotally; no controlled safety dataset exists |
| No dose-limiting toxicity in rodent studies | — | — | Preclinical studies report a wide therapeutic index; this does not establish human safety |
| Angiogenic mechanism | — | — | If the proposed angiogenic mechanism is real, its consequences in the presence of occult neoplasia have not been studied at all |
Compound Evidence Institute · CEI-TR-0111/3 · https://compoundevidence.com/trials/bpc-ph2-uc/results/ · retrieved 30 July 2026